The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2022 | New indications for CAR-T therapies in hematological malignancies
Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain, comments on the current status and future perspectives in chimeric antigen receptor T-cell (CAR-T) therapies for hematological malignancies. Whilst CAR-T therapies have been approved in the third-line setting for diffuse large B-cell lymphoma (DLBCL), recent data from key clinical trials has demonstrated the benefit of CAR-Ts over current standards of care (SOC) in the second-line setting. In addition, other ongoing clinical trials are reporting highly promising results for CAR-T therapies in multiple myeloma and adult acute lymphoblastic leukemia (ALL). It is expected that CAR-T therapies will be developed and approved for other hematological malignancies soon. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
